PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me

What happened

Novo Nordisk's prescriber site carries an advance notice: "we will be discontinuing Saxenda® in the US, with last shipments to wholesalers taking place in late January 2027." Saxenda is liraglutide, the daily injection for weight management that came before Wegovy.

Novo gives the reason in the same notice: "As more alternative FDA-approved treatment options have become available and the number of patients using Saxenda® has continued to decline, Novo Nordisk has made the strategic portfolio decision to discontinue the brand in the US." It adds that the decision "is not the result of any safety or quality-related concerns" and asks prescribers to talk with patients about alternatives.

Novo's page does not give the date the notice first went up, so we date this page by the day we read it.

What this means for cost

If you take Saxenda today, the switch your prescriber is most likely to discuss is a weekly GLP-1. Here is what those cost today without insurance, from the makers' own self-pay pages and the dated reads on our board.

Which drug and which dose you move to is your prescriber's call. Compounded drugs are not FDA-approved. For the liraglutide generics, see our generic liraglutide guide.

What happens next

  • Now to late January 2027Saxenda keeps shipping to wholesalers, per Novo's notice.
  • Late January 2027Last shipments to US wholesalers. Pharmacy stock after that depends on what is left in the supply chain.

Sources

  1. Novo Nordisk, Saxenda prescriber page with the discontinuation notice (NovoMedLink), read 20 Nov 2026

Read next